Zydus enters into in-licensing agreement with Neovii

06 Oct 2016 Evaluate

Zydus group has entered into an in-licensing agreement with Neovii, a Switzerland based global biopharmaceutical company to launch Grafalon, an immunosuppresant extensively used in solid organ transplants and Stem Cell Transplant in India. Neovii has been dedicated for over three decades to improve the outcomes in transplantation medicine, hemato-oncological and immune disorders. The Zydus group will market this therapy through Zydus Trans-immune, a division that offers a range of therapies related to transplant medicine. With the inclusion of Grafalon, Zydus Trans-immune becomes a leading player in transplant-immuno therapy segment and will be able to offer the most comprehensive therapy portfolio in solid organ transplant and stem cell transplant. The market for transplant-immuno therapies is estimated at Rs. 483 crore.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.

Zydus Lifesciences Share Price

914.55 -0.10 (-0.01%)
01-Jan-2026 15:31 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1726.80
Dr. Reddys Lab 1252.40
Cipla 1500.00
Zydus Lifesciences 914.55
Lupin 2106.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×